What is PT-141?
PT-141, also known as bremelanotide, is a synthetic analogue of Melanotan II, a melanocortin peptide. Melanotan II mainly drives tanning through MC1R receptors; PT-141 was developed to act on the MC3R and MC4R receptors in the central nervous system, specifically the hypothalamic pathways that regulate sexual arousal.
The mechanism is the interesting part. PT-141 does not work through the vascular system the way PDE5 inhibitors like sildenafil do; it acts centrally on the brain's sexual arousal pathways, so it can work even when vascular treatments fail. In 2019 the FDA approved bremelanotide as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, which makes PT-141 one of the few peptides here with a full regulatory approval.
Effects, what does the research say?
Sexual Function in Women
The clinical evidence for PT-141 is strongest in women, backed by the FDA approval of Vyleesi. Phase 2 and phase 3 trials showed:
- Statistically significant improvements in sexual desire and arousal scores (FSDS-DAO scale)
- Reduction in distress related to low sexual desire
- Effects observed within 45 minutes of subcutaneous injection, lasting 6-12 hours
- Effective in women who did not respond to other treatments
"Bremelanotide (PT-141) significantly improved sexual desire, arousal, orgasm, satisfaction, and reduced distress compared with placebo in women with hypoactive sexual desire disorder."
Kingsberg SA et al. (2019) · Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology · PMID 31599840 ↗
Sexual Function in Men
PT-141 has also been studied for erectile dysfunction (ED), particularly in men who do not respond adequately to PDE5 inhibitors. Research shows:
- Significant improvement in erectile function scores in double-blind trials
- Works via a completely different mechanism than Viagra/Cialis (central vs. vascular)
- Potential use as adjunct therapy or alternative in non-responders to PDE5 inhibitors
- Does not require sexual stimulation to initiate its central effects (unlike PDE5i)
"PT-141 (bremelanotide) significantly improved erectile function in men with erectile dysfunction, including a subgroup who had failed to respond to sildenafil, suggesting a complementary mechanism of action."
Simon JA et al. (2019) · Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology · PMID 31599847 ↗
Mechanism, Central vs. Vascular
Why PT-141 works differently:
- PDE5 inhibitors (sildenafil, tadalafil): work in the penis/vagina by increasing blood flow
- PT-141: acts on melanocortin receptors in the hypothalamus, the brain centres controlling desire and arousal
- This central mechanism means PT-141 can work even when blood flow is not the primary issue
- Also explains its effectiveness in women (where vascular treatments are largely ineffective)
Dosage, what is being researched?
Important: The following reflects doses studied in published research and the FDA-approved Vyleesi formulation. For non-approved uses, this is not medical advice.
| Indication | Typical Dose | Protocol | Notes |
|---|---|---|---|
| Women (HSDD) | 1.75 mg SC | 45-60 min before activity | FDA-approved Vyleesi dose |
| Men (ED research) | 1-2 mg SC | 1-2 hours before activity | Not approved, research only |
| Nasal spray research | 0.5-1 mg | 1-2 hours before activity | Lower bioavailability than SC |
Storage & Reconstitution
- Unreconstituted: Refrigerator (2-8 °C), protected from light, shelf life up to 24 months
- After reconstitution with bacteriostatic water: max. 30 days refrigerated
- Do not freeze after reconstitution
- Add water slowly along the glass wall, do not shake